MedTrace Logo

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2024-09-03

Study results available
· View outcomes & findings →

Summary

The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Amphetamine Sulfate

active experimental AR19

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Arbor Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven Caras, MD, PhD · Arbor Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2019-04-12
Completion
2019-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659929 on ClinicalTrials.gov